Beyond Air Gross Profit 2016-2021 | XAIR

Beyond Air gross profit from 2016 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Beyond Air Annual Gross Profit
(Millions of US $)
2021 $1
2020 $1
2019 $8
2017 $
2016 $
2016 $
2015 $
2015 $
Beyond Air Quarterly Gross Profit
(Millions of US $)
2021-09-30
2021-06-30
2021-03-31 $0
2020-12-31 $0
2020-09-30 $0
2020-06-30 $0
2020-03-31 $-0
2019-12-31 $0
2019-09-30 $1
2019-06-30 $1
2019-03-31 $8
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.416B $0.001B
Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company. It is engaged in developing a Nitric Oxide Generator and Delivery System. The company's principal product is AirNOvent which is in clinical stage. Beyond Air Inc., formerly known as AIT Therapeutics Inc., is based in Garden City, New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09